No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NGNE Neurogene
- 30.320
- -9.680-24.20%
Close Jun 18 16:00 ET
- 30.100
- -0.220-0.73%
Post 19:45 ET
393.56MMarket Cap-10706P/E (TTM)
39.990High29.690Low209.27KVolume38.710Open40.000Pre Close6.79MTurnover3.52%Turnover RatioLossP/E (Static)12.98MShares53.00052wk High2.30P/B180.44MFloat Cap12.20052wk Low--Dividend TTM5.95MShs Float1115.000Historical High--Div YieldTTM25.75%Amplitude7.500Historical Low32.452Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates.Quantum
Neurogene Down Over 22%, on Pace for Largest Percent Decrease Since June 2018 -- Data Talk
Neurogene Inc. ( NGNE ) is currently at $31.05, down $8.95 or 22.38% --Would be lowest close since May 13, 2024, when it closed at $30.64 --On pace for largest percent decrease since June 27, 2018,
Express News | Neurogene Shares Are Trading Lower. The Company Announced That the First Patient in Cohort 2 Received High-dose NGN-401 Gene Therapy in the Phase 1/2 Trial for Female Pediatric Patients With Rett Syndrome
Express News | Neurogene Announces First Patient Dosed in High-Dose Cohort of Ngn-401 Gene Therapy Clinical Trial for Rett Syndrome
Neurogene Initiated at Outperform by Baird
Neurogene Initiated at Outperform by Baird
Comments
$Neurogene(NGNE.US$
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg